# BI 1744 CL With Respimat Once Daily Versus Twice Daily in COPD

> **NCT00846768** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 47 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** BI 1744 CL

## Key facts

- **NCT ID:** NCT00846768
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2009-07
- **Final completion:** —
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2014-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00846768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00846768, "BI 1744 CL With Respimat Once Daily Versus Twice Daily in COPD". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00846768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*